Synthorx Inc (NASDAQ:THOR) dropped 1.7% on Friday . The stock traded as low as $12.79 and last traded at $12.79. Approximately 327 shares changed hands during mid-day trading, a decline of 100% from the average daily volume of 83,987 shares. The stock had previously closed at $13.01.

Several equities research analysts recently commented on THOR shares. Zacks Investment Research raised Synthorx from a “hold” rating to a “buy” rating and set a $20.00 target price for the company in a research note on Saturday, March 16th. HC Wainwright reaffirmed a “buy” rating and set a $30.00 target price on shares of Synthorx in a research note on Wednesday, May 1st. Svb Leerink reaffirmed an “outperform” rating on shares of Synthorx in a research note on Monday, March 18th. Finally, Leerink Swann started coverage on Synthorx in a research note on Friday, March 15th. They set an “outperform” rating for the company. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $23.67.

The firm has a market capitalization of $396.64 million and a PE ratio of -1.94.

Synthorx (NASDAQ:THOR) last announced its quarterly earnings results on Tuesday, April 30th. The medical instruments supplier reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.03). As a group, equities analysts forecast that Synthorx Inc will post -1.65 earnings per share for the current year.

A number of large investors have recently made changes to their positions in THOR. Opaleye Management Inc. bought a new position in shares of Synthorx during the 1st quarter valued at $815,000. Morgan Stanley lifted its holdings in shares of Synthorx by 1,234.7% during the 1st quarter. Morgan Stanley now owns 1,308 shares of the medical instruments supplier’s stock valued at $26,000 after buying an additional 1,210 shares during the period. Geode Capital Management LLC bought a new position in shares of Synthorx during the 1st quarter valued at $2,913,000. Charles Schwab Investment Management Inc. purchased a new stake in shares of Synthorx in the 1st quarter worth $1,237,000. Finally, Northern Trust Corp purchased a new stake in shares of Synthorx in the 1st quarter worth $1,855,000. Institutional investors and hedge funds own 66.08% of the company’s stock.

WARNING: “Synthorx (NASDAQ:THOR) Stock Price Down 1.7%” was originally published by Watch List News and is the property of of Watch List News. If you are viewing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this story can be accessed at https://www.watchlistnews.com/synthorx-nasdaqthor-stock-price-down-1-7/3041790.html.

Synthorx Company Profile (NASDAQ:THOR)

Synthorx, Inc, a biopharmaceutical company, focuses on the development of cytokine Synthorin programs for the treatment of cancer and autoimmune disorders in the United States. The company's lead product candidate is THOR-707, a variant of recombinant human IL-2 that is in the development in various solid tumor types as a single agent and in combination with an immune checkpoint inhibitor.

Featured Article: Roth IRA

Receive News & Ratings for Synthorx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthorx and related companies with MarketBeat.com's FREE daily email newsletter.